EW
Edwards Lifesciences Corp (EW) Q2 2026 Earnings Call Highlights: Strong Sales Growth and ...
Article Summary
HOLD- Edwards Lifesciences Corp. (NYSE: EW) reported stronger than expected Q2 2026 sales growth of 12.5% year-over-year, driven by strong demand across TAVR, mitral, tricuspid, surgical, and surgical surgical products.
- Edwards Lifesciences raised full-year sales guidance for T AVVR, TMTT, and total company, reflecting confidence in sustained performance across multiple therapeutic areas.
- EW maintained a strong balance sheet with approximately $2.9 billion in cash and cash equivalents, supported by $1.5 billion in share repurchases and a $5.4 billion share repurchase authorization.
- Despite rising SG&A and R&D costs, margins remained flat, and the company maintained a 30% adjusted operating profit margin.
- EW remains on track to achieve its long-term target of 10% total company sales growth supported by a comprehensive portfolio and strategic platforms, though it faces risks and uncertainties.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 14.6% | 25% | 50.0 ptsMeets Minimum (14.6%) - Passes screener |
| EPS Growth Next 5Y ? | 13.9% | 25% | 35.0 ptsBelow Screener (13.9%) - Modest outlook |
| Target Price Upside ? | 20.1% | 20% | 70.0 ptsGood Upside (20.1%) - Target: $100.65 vs Current: $83.82 |
| Gross Margin % ? | 80.0% | 15% | 100.0 ptsExceptional (80.0%) - Strong pricing power |
| Drawdown from 52-Wk High ? | -13.0% | 15% | 40.0 ptsMild Pullback (-13.0%) - Light entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About EW
- Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally.
- It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands.
- The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve.
- It distributes its products through a direct sales force and independent distributors.
- Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.